Loading...
Market
What will be Alnylam's Vutrisiran sales by end of 2025?
2
Resolution / Starting Odds
Exceeds $1 billion in sales • 25%
Between $500 million and $1 billion in sales • 25%
Between $100 million and $500 million in sales • 25%
Less than $100 million in sales • 25%
Company financial reports and sales data
Story
Alnylam's Vutrisiran Shows Promise in HELIOS-B Phase 3 Study at European Society of Cardiology
Aug 30, 2024, 11:17 AM
Alnylam Pharmaceuticals presented detailed results from its HELIOS-B Phase 3 study of the drug Vutrisiran, also known as Amvuttra, at the European Society of Cardiology Congress. The study focused on patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran showed a substantial reduction in the risk of death and serious cardiovascular events. Specifically, the drug achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events, and a 31% and 36% reduction in all-cause mortality during the 33-36-month double-blind period and up to month 42, respectively. Despite these positive results, Alnylam's shares fell nearly 11% as the data did not meet heightened investor expectations. The company's heart drug faces competition from BridgeBio's Acoramidis, which showed promising results in its ATTRibute-CM study. Analysts suggest that Vutrisiran may not be superior to Acoramidis, with comparative data indicating a higher relative risk reduction for Acoramidis.
View original story
Similar markets
Less than $500 million • 33%
$500 million to $1 billion • 33%
More than $1 billion • 33%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Approval • 33%
Conditional Approval • 33%
Rejection • 34%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%